In addition, drug doses used in in vitro experiments often exceeded the usual drug concentrations reached in the brain, particularly in experiments involving intratumoral application of selective COX-2 inhibitors or coupling of selective COX-2 inhibitors to nanoparticles aimed at increasing drug concentrations in the tumour [52]. This evidence concerns the gene PTGS2 and neoplasm.